Objective: Hepatitis B (HB) is a preventable disease and a public health challenge due to its high morbidity and mortality. This study was conducted within the framework of the World Health Organization's strategy, which includes establishing prophylactic measures to prevent vertical transmission. The aim was to assess the degree of implementation of HB preventive measures to avoid vertical transmission in newborns in Spain.
Methods: A retrospective cross-sectional study was carried out with women who gave birth in 2022 in four autonomous communities in Spain. Clinical databases from primary care, hospitals, vaccination, and microbiology were used. Continuous variables were expressed as the mean and standard deviation or median and interquartile range depending on their distribution. Categorical variables were described by the absolute and relative frequency of each category.
Results: The coverage of hepatitis B screening during pregnancy ranged from 76% to 99.3%, the prevalence of hepatitis B virus infection in pregnant women ranged from 0.23% to 0.60%, and the compliance rate varied between 30.6% and 100%, depending on the autonomous community.
Conclusions: It is necessary to raise awareness among healthcare professionals to properly record care activities and to improve the interoperability of information systems, screening, and vaccination records to evaluate the implementation of preventive measures against hepatitis B, such as vaccination and immunoglobulin administration.
Download full-text PDF |
Source |
---|
Sci Rep
January 2025
Centers of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand.
This study aimed to evaluate the impact of Thailand's hepatitis B virus (HBV) National Program Immunization (NPI), 32 years post-implementation, on infection rates and immunity in various age groups. A cross-sectional study involved 6,068 participants aged 6 months to 80 years from four regions in Thailand. Blood samples were tested for HBsAg, anti-HBs, and anti-HBc using a chemiluminescent immunoassay.
View Article and Find Full Text PDFViruses
November 2024
Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro 21040-361, RJ, Brazil.
Coronavirus disease 2019 (COVID-19) still causes death in elderly and immunocompromised individuals, for whom the sustainability of the vaccine response may be limited. Antiviral treatments, such as remdesivir or molnupiravir, have demonstrated limited clinical efficacy. Nirmatrelvir, an acute respiratory syndrome coronavirus 2 (SARS-CoV-2) major protease inhibitor, is clinically effective but has been associated with viral rebound and antiviral resistance.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Department of Maternal-Infant and Public Health Nursing, Ribeirão Preto College of Nursing, University of São Paulo, Ribeirão Preto 14040-902, São Paulo, Brazil.
Introduction: Vaccines are a significant public health achievement, which are crucial for child survival and disease control globally. In Brazil, the National Immunization Program (PNI) manages vaccination schedules, including essential vaccines like BCG and Hepatitis B, administered at birth. Despite achieving over 95% coverage for years, vaccination rates have declined since 2016, a trend exacerbated by the COVID-19 pandemic.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Department of Avian Diseases, College of Veterinary Medicine and Center for Avian Disease, Jeonbuk National University, Iksan 54596, Republic of Korea.
Duck virus hepatitis (DVH), caused by duck hepatitis A virus (DHAV), poses significant challenges to duck farming due to high mortality rates in young ducklings. Despite the widespread use of live attenuated vaccines, the genetic diversity within DHAV strains has diminished their cross-protection efficacy. This study aimed to evaluate the cross-protective efficacy of current DHAV-1 and DHAV-3 vaccines against genetically divergent wild strains.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
PATH-Headquarters, Seattle, WA 98121, USA.
Background: Persistent inequities in access to vaccinations pose challenges for immunization programs worldwide. Innovations facilitating vaccine delivery, such as leveraging vaccine thermostability through a Controlled Temperature Chain (CTC), have emerged as a potential solution to increase coverage in low- and middle-income countries (LMICs) countries such as Côte d'Ivoire, reducing dependence on the cold chain and improving vaccine delivery efficiency. However, the added value of thermostable vaccines and their integration into national immunization programs is under-recognized by stakeholders.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!